DU
ALLO icon

Delphia (USA)’s Allogene Therapeutics ALLO Stock Holding History

Delphia (USA)’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,714
Closed -$68.2K – 11
2023
Q2 		$68.2K Sell
13,714
-13,153
-49% -$71.1K 0.11% 205
2023
Q1 		$133K Sell
26,867
-4,472
-14% -$28.7K 0.16% 220
2022
Q4 		$197K Buy
31,339
+8,202
+35% +$75.9K 0.23% 207
2022
Q3 		$250K Sell
23,137
-14,576
-39% -$198K 0.29% 154
2022
Q2 		$430K Buy
37,713
+22,264
+144% +$198K 0.3% 108
2022
Q1 		$141K Buy
15,449
+5,226
+51% +$54.4K 0.11% 303
2021
Q4 		$153K Buy
+10,223
New +$180K 0.16% 233

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Delphia (USA)'s ALLO Position: Q3 2023 in Review

Delphia (USA) sold out of Allogene Therapeutics (ALLO) in Q3 2023, closing a stake of 13,714 shares — an estimated $68.2K sold.

Delphia (USA) first reported a position in ALLO in Q4 2021 and held it in 7 quarters. The position peaked at $430K in Q2 2022. 154 funds tracked by Wall St. Rank hold ALLO as of Q3 2023.

  • Delphia (USA) reported no remaining Allogene Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Delphia (USA) sold 13,714 Allogene Therapeutics shares in Q3 2023, an estimated $68.2K.
  • Delphia (USA) first reported a position in Allogene Therapeutics in Q4 2021 and held it in 7 quarters.
  • Delphia (USA)'s Allogene Therapeutics position peaked at $430K in Q2 2022.
  • 154 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2023.

Based on Delphia (USA)'s 13F filing for Q3 2023, filed 15 Nov 2023.